Sarepta Therapeutics named Michael Severino, formerly CEO of Tessera Therapeutics, as its new chief executive starting Tuesday. The appointment follows Doug Ingram’s planned retirement and comes as Sarepta works to address competitive pressures and renewed scrutiny around its Duchenne muscular dystrophy gene therapy pipeline. Severino’s background includes leadership roles across gene editing and Duchenne-focused development, aligning with Sarepta’s need to restore confidence in efficacy and safety narratives. For investors and partners, the CEO transition may influence near-term clinical strategy, regulatory engagement, and commercialization planning. The leadership change underscores that turnaround stories in DMD remain tightly coupled to execution across regulatory processes, trial designs, and manufacturing scale-up.